Showcasing WHO’s mRNA Vaccine R&D Priorities & Requirements for Low- & Middle- Income

Time: 9:15 am
day: Day Two AM


  • Numerous LMICs are acquiring mRNA vaccine production capacity as a tool to enable rapid response to future regional or global outbreaks. Maintaining this infrastructure requires that countries develop and manufacture mRNA vaccines for routine targets
  • WHO, MPP, and their partners are building research networks to help these countries undertake R&D for mRNA vaccines against priority diseases in LMIC countries
  • Reviewing the technical feasibility (PTRS) of developing the vaccines against these diseases, and also the probability that such vaccines would be procured (probability of policy development and procurement). This is a framework for R&D prioritisation to support these regions